Abattis Bioceuticals Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATTBF research report →
Companywww.abattis.com
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets.
- CEO
- Francesco Paolini
- IPO
- 2014
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $14.33K
- P/E
- -0.01
- P/S
- 0.06
- P/B
- 0.00
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 67.62%
- Op Margin
- -1108.73%
- Net Margin
- -852.40%
- ROE
- -26.96%
- ROIC
- -25.05%
Growth & Income
- Revenue
- $356.88K · 4163.24%
- Net Income
- $-3,042,005 · 96.10%
- EPS
- $-0.01 · 97.29%
- Op Income
- $-3,956,802
- FCF YoY
- 151.11%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -46.51
- Avg Volume
- 26.23K
Get TickerSpark's AI analysis on ATTBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ATTBF Coverage
We haven't published any research on ATTBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATTBF Report →